Patents by Inventor Dean Engelhardt
Dean Engelhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8637506Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: GrantFiled: May 19, 2004Date of Patent: January 28, 2014Assignees: Enzo Biochem, Inc., University of Connecticut, St. Jude's Childrens HospitalInventors: Dianqing Wu, Yazhou Zhang, Peng Liu, Xiaofeng Li, Jie Zhang, Jufang Shan, Dean Engelhardt
-
Patent number: 8343922Abstract: Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.Type: GrantFiled: May 19, 2004Date of Patent: January 1, 2013Assignee: Enzo Biochem, Inc.Inventors: Dianqing Wu, Xiaofeng Li, Peng Liu, Wenzhong Liu, Dean Engelhardt
-
Patent number: 8097405Abstract: A process for determining the sequence of nucleic acids of interest employs nucleotides or nucleotide analogs that have been made detectable by non-radioactive modifying or labeling. Such nucleotides or nucleotide analogs are modified on the sugar moieties, the phosphate moieties or the base moieties, including base analogs. Modified nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA. The modified or labeled nucleotides or nucleotide analogs are also useful in processes for detecting the presence of nucleic acids of interest and for characterizing chromosomal sequences. Detection processes using the modified or labeled nucleotides or nucleotide analogs extend to the use of a gel for separating or resolving hybrids formed between non-radioactively labeled oligonucleotides or polynucleotides and such nucleic acids of interest.Type: GrantFiled: June 7, 1995Date of Patent: January 17, 2012Assignee: Enzo Biochem, Inc.Inventors: Dean Engelhardt, Elazar Rabbani, Stanley Kline, Jannis G. Stavrianopoulos, Dollie Kirtikar
-
Publication number: 20100273145Abstract: A method of detecting in a sample an analyte (A) having a molecularly recognizable portion thereon, which comprises: providing (B) a molecular bridging entity having thereon: (i) a portion capable of recognizing the molecularly recognizable portion on the analyte; and (ii) a portion comprising a polynucleotide sequence; and (C) a signalling entity having thereon: (i) a polynucleotide portion capable of annealing to the polynucleotide portion of the bridging entity, thereby to form a stable polynucleotide hybrid, and (ii) a signal generating portion; forming a complex comprising: (1) the analyte (A) complexed through its molecularly recognizable portion to (2) the recognizing portion of the entity (B); the entity (B) being complexed through the polynucleotide portion thereon to (3) the polynucleotide portion of the signalling entity; and detecting a signal by means of the signal generating portion present in the complex.Type: ApplicationFiled: June 7, 1995Publication date: October 28, 2010Applicant: ENZO BIOCHEM, INC.Inventors: ROBERT PERGOLIZZI, JANNIS STAVRIANOPOULOS, ELAZAR RABBANI, DEAN ENGELHARDT, STAN KLINE, PAULA OLSIEWSKI
-
Publication number: 20080108139Abstract: The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: Enzo Therapeutics, Inc.Inventors: Elazar Rabbani, Jannis Stavrianopoulos, James Donegan, Dakai Liu, Norman Kelker, Dean Engelhardt
-
Publication number: 20080026372Abstract: This invention provides inter alia an in vitro process for producing multiple specific nucleic acid copies in which the copies are produced under isostatic conditions, e.g., temperature, buffer and ionic strength, and independently of any requirement for introducing an intermediate structure for producing the copies. In other aspects, the invention provides in vitro processes for producing multiple specific nucleic acid copies in which the products are substantially free of any primer-coded sequences, such sequences having been substantially or all removed from the product to regenerate a primer binding site, thereby allowing new priming events to occur and multiple nucleic acid copies to be produced. This invention further provides a promoter-independent non-naturally occurring nucleic acid construct that produces a nucleic acid copy or copies without using or relying on any gene product that may be coded by the nucleic acid construct.Type: ApplicationFiled: November 19, 2003Publication date: January 31, 2008Applicant: Enzo Diagnostics, Inc.Inventors: Dean Engelhardt, Jannis Stavrianopoulos, Elazar Rabbani, James Donegan
-
Patent number: 7220854Abstract: The present invention provides a nucleotide having the formula, wherein PM is a phosphate moiety, SM is a ribose or a deoxyribose sugar moiety, and BASE is a pyrimidine, purine or 7-deazapurine moiety. PM is attached to SM at a position independently selected from the 2?, 3?, and 5? positions of SM when the nucleotide is a ribonucleotide, and at a position independently selected from the 3? and 5? positions when the nucleotide is a deoxyribonucleotide. BASE is attached to the 1? position of SM from the N1 position when BASE is a pyrimidine, or the N9 position when BASE is a purine or 7-deazapurine. Sig is a detectable moiety covalently attached to SM directly or through a linkage group. Also provided are an oligo- or polynucleotide comprising at least one such sugar moiety labeled nucleotide, and other compositions including those wherein a polypeptide is terminal ligated or attached to the oligo- or polynucleotide.Type: GrantFiled: June 7, 1995Date of Patent: May 22, 2007Assignee: Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc.Inventors: Dean Engelhardt, Elazar Rabbani, Stanley Kline, Jannis G. Stavrianopoulos, Dollie Kirtikar
-
Publication number: 20070090306Abstract: A method of disposing of radioactive waste comprising the steps of: providing a pressure-equalizing container; filling the pressure-equalizing container with radioactive waste; and burying the waste filled container in a subduction fault region of the earth's crust. For a preferred embodiment of the process, the waste filled containers are buried in the mud on the ocean floor in a subduction fault region. Preferably, the containers are placed on the ocean side of the fault, rather than the continental shelf side. The pressure-equalizing container is preferably fabricated from stainless steel, with a lead seal, although containers fabricated from ceramic materials may also be used. The waste-filled containers are transported by ship to the area above a subduction fault, and an unpressurized, remote-controlled “submarine crawler” takes a number of containers to the ocean floor and buries them there, individually, in the mud or sediments.Type: ApplicationFiled: December 5, 2006Publication date: April 26, 2007Inventor: Dean Engelhardt
-
Publication number: 20060198791Abstract: Abstract of the Disclosure The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors’ transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: ApplicationFiled: May 19, 2004Publication date: September 7, 2006Inventors: Dianqing Wu, Yazhou Zhang, Peng Liu, Xiaofeng Li, Jie Zhang, Jufang Shan, Dean Engelhardt
-
Patent number: 6992180Abstract: The present invention provides a nucleotide having the formula, Sig-PM-SM-BASE wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a pyrimidine, purine or 7-deazapurine moiety. PM is attached to the 3? or the 5? position of the sugar moiety when the nucleotide is a deoxyribonucleotide and at the 2?, 3? or 5? position when the nucleotide is a ribonucleotide. BASE is attached to the 1? position of SM from the N1 position when BASE is a pyrmidine or the N9 position when BASE is a purine or 7-deazapurine. Sig is covalently attached to PM directly or via a chemical linkage, and represents a detectable moiety covalently attached to SM directly or through a linkage group. Also provided are an oligo- or polynucleotide comprising at least one such phosphate-moiety labeled nucleotide, and other compositions including those wherein a polypeptide is terminally ligated or attached to the oligo- or polynucleotide.Type: GrantFiled: June 7, 1995Date of Patent: January 31, 2006Assignee: Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc.Inventors: Dean Engelhardt, Elazar Rabbani, Stanley Kline, Janes G. Stavrianopoulos, Dollie Kirtikar
-
Publication number: 20060019353Abstract: This invention provides inter alia an in vitro process for producing multiple specific nucleic acid copies in which the copies are produced under isostatic conditions, e.g., temperature, buffer and ionic strength, and independently of any requirement for introducing an intermediate structure for producing the copies. In other aspects, the invention provides in vitro processes for producing multiple specific nucleic acid copies in which the products are substantially free of any primer-coded sequences, such sequences having been substantially or all removed from the product to regenerate a primer binding site, thereby allowing new priming events to occur and multiple nucleic acid copies to be produced. This invention further provides a promoter-independent non-naturally occurring nucleic acid construct that produces a nucleic acid copy or copies without using or relying on any gene product that may be coded by the nucleic acid construct.Type: ApplicationFiled: November 18, 2003Publication date: January 26, 2006Applicant: Enzo Diagnostics, Inc.Inventors: Dean Engelhardt, Jannis Stayrianopoulos, Elazar Rabbani, James Donegan
-
Publication number: 20050277112Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: December 15, 2005Applicant: Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
-
Publication number: 20050260227Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: November 24, 2005Applicant: Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
-
Publication number: 20050261181Abstract: Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.Type: ApplicationFiled: May 19, 2004Publication date: November 24, 2005Inventors: Dianqing Wu, Xiaofeng Li, Peng Liu, Wenzhong Liu, Dean Engelhardt
-
Publication number: 20050260560Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immurie cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: November 24, 2005Applicant: Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Isarel Gotsman, James Donegan
-
Publication number: 20050260226Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: November 24, 2005Applicant: Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
-
Publication number: 20050255454Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: November 17, 2005Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
-
Publication number: 20050196349Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: ApplicationFiled: May 19, 2004Publication date: September 8, 2005Inventors: Dianqing Wu, Yazhou Zhang, Peng Liu, Xiaofeng Li, Jie Zhang, Jufang Shan, Dean Engelhardt
-
Publication number: 20050147586Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: July 7, 2005Applicant: Enzo TherapeuticsInventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
-
Publication number: 20050136074Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.Type: ApplicationFiled: December 8, 2003Publication date: June 23, 2005Applicant: Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.Inventors: Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan